All In Biotech

Drug Trial Radar · NCT04518501

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Fuzuloparib Plus Arsenic Trioxide in Patients With Platinum Resistance Relapsed Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Dec 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jul 1, 2020

Primary completion

Dec 3, 2024

Study completion Jan 1, 2025

Sponsor

Lead sponsor
Xing XieAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived. Currently, the population that can benefit from PARPi is mainly focusing on BRCAm, then homologous-recombination deficiency patients. Limited data revealed the ORR was only 3-4% in homologous recombination proficiency patients with PARPi therapy. New treatments are urgently needed to improve patient outcomes. To explore the efficacy and safety of Fuzuloparib in combination with Arsenic trioxide therapy in platinum-resistance relapsed Ovarian cancer patients.

Conditions

  • Efficacy and Safety

Interventions

  • Arsenic trioxide Tablet +Fuzuloparib CapsulesDrug

    Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest. Fuzuloparib Capsules: 150 mg bid po

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: From date of randomization until PD or death from any cause, assessed up to 36 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Women's Hospital School Of Medicine Zhejiang University

    Zhejiang, Hangzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.